Join Sam Chang, MD, and Lan Gellert, MD, PhD, as they present their multidisciplinary expertise on a range of cases pertaining to Kidney Cancer.

An improved understanding of the biology of renal cell carcinoma (RCC) has led to the development of new targeted therapies. To date, seven such agents have been approved by the FDA for the treatment of advanced RCC: sunitinib malate, sorafenib tosylate, temsirolimus, everolimus, bevacizumab in combination with interferon, pazopanib, and axitinib. While expansion of knowledge and treatment options has improved patient care, it has presented numerous clinical challenges. The largest challenge lies in deciding upon the best first-line treatment for a given patient as well as effectively managing toxicities and adverse effects. In addition, nearly every patient with metastatic RCC requires second, third, and subsequent lines of therapy. Therefore, the challenge also lies in selecting the best sequence of treatment to provide maximum benefit to the patient.  Advances have been made in supportive care treatment as well. New drugs with novel mechanism of action (e.g., denosumab) are available for treatment of metastatic bone disease. New targeted therapies, such as tivozonib, among others, are currently under investigation in various clinical trials. Knowledge of the ongoing and upcoming trials is critical to counsel appropriate patients with RCC and provide optimal care.

An improved understanding of the biology of RCC has led to the development of new targeted therapies. To date, seven such agents have been approved by the FDA for the treatment of advanced RCC. Patients will be exposed to multiple agents using a continuum of care paradigm.  Helping them to develop realistic expectations is a critical part of caring for these patients.